Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Single-Cell Profiling Reveals Chemotherapy Resistance Signals in Ovarian Cancer

By LabMedica International staff writers
Posted on 22 Oct 2026

High-grade serous ovarian cancer is the most common and aggressive form of ovarian cancer. More...

It often causes few symptoms, leading to diagnosis at an advanced stage, and has a five-year survival rate below 40%. Treatment is further complicated by chemotherapy resistance, which may reflect differences in tumor cell behavior that DNA mutations alone cannot explain. New findings suggest that single-cell profiling at diagnosis can capture these differences and identify tumor characteristics associated with treatment failure.

One Biosciences (Paris, France), working with the French National Centre for Scientific Research, Institut Curie, and Sorbonne Université, found that some ovarian cancer cells may be epigenetically primed to resist cytotoxic chemotherapy. The work used clinical-grade single-cell profiling to examine high-grade serous ovarian tumors. One Biosciences has developed OneMap, an end-to-end molecular profiling platform designed to characterize tumors at single-cell resolution.

By analyzing single-cell RNA profiles from tumor samples collected before and after chemotherapy, the researchers tracked cellular changes associated with resistance. These analyses showed that DNA mutations alone could not explain the observed changes, highlighting the importance of examining tumor cell states alongside genetic alterations.

Tumors with a higher baseline prevalence of cellular states linked to chemotherapy resistance were associated with poorer overall survival. The team also identified epigenetic markers associated with resistance to the chemotherapy agents evaluated. The profiling technology can be applied to standard formalin-fixed, paraffin-embedded biopsy samples, making it compatible with tissue routinely collected in clinical care.

The full study was published online in Cancer Discovery on October 19, 2026. The findings indicate that initial tumor composition can predict overall survival in high grade serous ovarian cancer. The investigators also stated that clinical-grade single-cell profiling may help identify and track mechanisms of resistance across multiple cancer types.

“Ovarian cancer tumors are very diverse, with many different cell types. These cells can do many different things, some of which help the tumor resist chemotherapy. In this study we identified all the functional states present in a tumor both before and after treatment and found that a patient’s initial tumor profile predicted their outcome. By using single-cell profiling to identify functional states associated with chemotherapy resistance, we may be better able to predict who will respond to therapy and who won’t, giving physicians an opportunity for more personalized treatment strategies,” said Céline Vallot, Ph.D., co-founder and chief scientific officer at One Biosciences.

Related Links
One Biosciences


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Gold Member
Quantitative lmmunoassay Test Menu
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Led by Professor Sherry Chan Kit-wa (middle), the HKUMed research team provides the first large-scale Chinese population evidence to support reviewing Hong Kong’s long-term blood-monitoring requirements for clozapine use. (Photo courtesy of HKUMed)

Study Supports Review of Long-Term Blood-Monitoring Guidelines for Clozapine

Treatment-resistant schizophrenia (TRS) is a severe form of schizophrenia for which clozapine remains the only antipsychotic specifically approved by the U.S. Food and Drug Administration (FDA).... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image

Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil

Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.